ISSN: 1859 - 2872
M2BPGi as a novel marker for liver fibrosis in Vietnamese patients with chronic hepatitis B
Main Article Content
Keywords
Abstract
Objective: To compare the efficiency of serum M2BPGi to FibroScan® in diagnosing liver fibrosis stages in CHB patients. Subject and method: All 177 adult CHB patients and 50 healthy controls visiting the University Medical Center Ho Chi Minh City, Vietnam between October 2019 and December 2021 underwent liver stiffness measurement using M2BPGi, ARFI-pSWE, and FibroScan®. Using FibroScan® as a reference, M2BPGi results and other fibrosis markers including ARFI-pSWE, APRI, FIB-4 were tested for correlation, cut-off for determining significant fibrosis (F ≥ 2) and cirrhosis (F4). Result: M2BPGi levels had a statistically significant difference between healthy controls (0.44 ± 0.15) and CHB patients with no or mild fibrosis (0.66 ± 0.24). There was a strong agreement between M2BPGi and FibroScan® (r = 0.77, p<0.001). The optimal M2BPGi cut-off value for detecting significant fibrosis (F ≥ 2) was 0.87 C.O.I (Cut-off index) with area under the curve (AUC) of 0.77, sensitivity of 62%, specificity of 82%. For predicting cirrhosis (F4), the optimal cut-off value was 1.3 C.O.I with a sensitivity of 88%, specificity of 87%, and an AUC of 0.91. Conclusion: M2BPGi could be an effective method for evaluating liver fibrosis in Vietnamese patients with CHB. M2BPGi cut-off values of 0.87 C.O.I and 1.3 C.O.I could be used to diagnose significant fibrosis and cirrhosis, respectively.
Article Details
References
2. Phạm Văn Lình, Trần Thị Minh Diễm, Trần Đình Hậu, Ngô Viết Lộc (2006) Nghiên cứu tình hình nhiễm virus viêm gan B tỉnh Thừa Thiên Huế. Tạp Chí Học Thực Hành, 3(536), tr. 82-85.
3. Bộ Y Tế Việt Nam (2019) Hướng dẫn chẩn đoán và điều trị bệnh viêm gan vi rút B. 3310/QĐ-BYT.
4. Bùi Hữu Hoàng, Nguyễn Đình Chương (2021) Khảo sát mối tương quan giữa chỉ số GPRI và APRI với ARFI trong đánh giá xơ hoá gan ở bệnh nhân nhiễm vi-rút viêm gan B mạn. Tạp chí Y học Thành phố Hồ Chí Minh 25(2): 106.
5. Terrault NA, Bzowej NH, Chang KM et al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatol Baltim Md, 63(1):261–283.
6. U.S. Food and Drug Administration (FDA) (2013) Echosens’ FibroScan® System. 510(k) Summary. K123806. Approved.
7. Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M et al (2021) EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 75(3): 659-689.
8. Kuno A, Ikehara Y, Tanaka Y et al (2013) A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 3: 1065.
9. Shirabe K, Bekki Y, Gantumur D et al (2018) Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: More than a biomarker of liver fibrosis. J Gastroenterol 53: 819-826.
10. Abe M, Miyake T, Kuno A et al (2015) Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50: 776‐784.
11. Ura K , Furusyo N, Ogawa E et al (2016) Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 43: 114‐124.
12. Feng S, Wang Z, Zhao Y et al (2020) Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: An updated meta-analysis. Sci Rep 10: 10582.
13. Xiao G, Yang J, Yan L et al (2015) Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis. Hepatology 61(1): 292-302.
14. Ferraioli G, Filice C, Castera L et al (2015) WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: Liver. Ultrasound Med Biol 41(5): 1161-1179.
15. Bedossa P and Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24(2); 289–293.
16. Lian MJ, Zhang JQ, Chen SD et al (2019) Diagnostic accuracy of γ-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: A meta-analysis. Eur J Gastroenterol Hepatol 31(5): 599-606.
17. Xu H, Kong W, Liu L et al (2017) Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol 17(1): 62.
18. Wei B, Feng S, Chen E et al (2017) M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection. J Clin Lab Anal 00: 22261.
19. Zou X, Zhu MY, Yu DM et al (2017) Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int 37(1): 35-44.
20. Nishikawa H, Enomoto H, Iwata Y et al (2016) Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat 23(12): 977-984.
21. Yamada N, Sanada Y, Tashiro M et al (2017) Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol;52(2):245-252.
22. Mak LY, Wong DK, Cheung KS et al (2018) Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol 9(6): 163.
Article Sidebar
